BOSTON, February 15 /PRNewswire/ --

PAREXEL International Corporation ("PAREXEL") (Nasdaq: PRXL) notes the recent movement in the share price of ClinPhone plc ("ClinPhone" or the "Company"). Under the United Kingdom Takeover Code, PAREXEL confirms that it has made a preliminary proposal to the Board of ClinPhone in relation to a potential offer by PAREXEL for the entire issued and to be issued share capital of ClinPhone. While that preliminary proposal was rejected by the Board of ClinPhone, PAREXEL is currently evaluating its options in relation to ClinPhone. However, there can be no certainty that an offer for ClinPhone will be forthcoming.

Any offer, if made, is likely to be solely in cash. A further announcement will be made in due course.

ROCHESTER, New York, February 15 /PRNewswire/ --

EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

HONG KONG, February 15 /PRNewswire/ --

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is feasible and safe for use in acute myocardial infarction (AMI) patients, according to a paper published in the American Heart Journal (2008; Vol. 155, Issue 1: 128-132).

The paper, based on a study of 120 acute ST-elevation myocardial infarction (STEMI) patients who received a Genous stent, reports there was no incidence of late thrombosis and that the revascularization rate of 2.5% at six months is highly acceptable when compared to published primary percutaneous coronary intervention (PCI) rates for bare metal stents. The paper also highlighted the low rate of major adverse cardiac events (MACE): 4.2% at 30 days and 5.8% at six months.

LONDON, February 15 /PRNewswire/ -- Prospects new Managing Director will be Vincent McDonnell, currently Director of Learning at CfBT Education Trust. He will take over in his new post at the end of March.

Vincent worked in senior positions in Birmingham, Sheffield and then Staffordshire Local Education Authorities, before moving to the London Borough of Richmond as Chief Education Officer in February 1998.

Then, in April 2000, he moved to Cambridge Education, to lead the outsourced education service in Islington, turning around what had been identified as a failing service into what was subsequently identified as one of the most improved Authorities in the country.

BARCELONA , Mobile World Congress, February 15 /PRNewswire/ -- Launched in 2007, the R&S CMW270 WiMAX communication tester from Rohde & Schwarz now offers the capability to emulate a base station (signaling mode). This capability means utmost flexibility and test depth. Plus, the measurement speed of the instrument is up to ten times higher than that of existing test solutions. This results in maximum throughput in the production of WiMAX chipsets and mobile stations.

HONG KONG, February 15 /PRNewswire/ --

- Innovative Hydrogen-Powered Radio-Controlled Car Leads Green Toy Revolution

Wah Shing Toys Co., Ltd. (Wah Shing), one of the world's largest toy manufacturers, today announced that its H2Go hydrogen-powered RC car has won the Toy Innovation 2008 Award in the Electronics and Technology category at this year's International Toy Fair in Nuremburg. The H2Go car, manufactured by Wah Shing, uses technology invented by Horizon Fuel Cell Technologies ("Horizon") the leading producer of consumer-oriented fuel cell technology and is being marketed by the renowned Corgi International.